uniQure (NASDAQ:QURE) Shares Sold by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd trimmed its holdings in shares of uniQure (NASDAQ:QURE) by 27.7% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 12,943 shares of the biotechnology company’s stock after selling 4,951 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in uniQure were worth $64,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its stake in uniQure by 6.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 277,275 shares of the biotechnology company’s stock valued at $1,367,000 after purchasing an additional 16,464 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in uniQure in the 3rd quarter valued at $69,000. Privium Fund Management B.V. raised its stake in uniQure by 16.3% in the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after purchasing an additional 104,500 shares during the last quarter. Atria Investments Inc acquired a new position in uniQure in the 3rd quarter valued at $53,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,663 shares during the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on QURE. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research note on Wednesday, November 6th. Royal Bank of Canada reduced their price objective on uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Raymond James restated an “outperform” rating and issued a $20.00 target price on shares of uniQure in a report on Thursday, October 10th. The Goldman Sachs Group dropped their target price on uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a report on Wednesday, November 6th. Finally, StockNews.com upgraded uniQure to a “sell” rating in a report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $17.00.

uniQure Stock Down 10.1 %

Shares of NASDAQ:QURE opened at $6.41 on Wednesday. The stock has a market cap of $312.42 million, a P/E ratio of -1.29 and a beta of 0.89. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 52-week low of $3.73 and a 52-week high of $11.35. The business has a fifty day moving average of $6.05 and a two-hundred day moving average of $6.02.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The business had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. On average, research analysts expect that uniQure will post -3.74 earnings per share for the current year.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.